Eli Lilly

$119.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.10 (+0.93%) Today
$0.00 (0.00%) As of 6:11 PM EST after-hours

Why Robinhood?

You can buy or sell Eli Lilly and other stocks, options, ETFs, and crypto commission-free!

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through the following segments: Human Pharmaceutical Products and Animal Health Products. Read More The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health Products segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Employees
38,680
Headquarters
Indianapolis, Indiana
Founded
1876
Market Cap
112.92B
Price-Earnings Ratio
26.29
Dividend Yield
1.94
Average Volume
2.73M
High Today
$119.92
Low Today
$117.54
Open Price
$118.19
Volume
3.00M
52 Week High
$132.13
52 Week Low
$101.36

Collections

LLY News

Reuters13h

Eli Lilly to put Loxo executives in charge of new cancer research unit

(Reuters) - U.S. drugmaker Eli Lilly and Co said on Thursday it will create a new cancer research division that will be run by top executives from Loxo Oncology
20
BenzingaDec 2

Global Attention Deficit Hyperactivity Disorder Market Spotlight 2019 Featuring Allergan, Eli Lilly, Johnson & Johnson, Takeda, Teva - ResearchAndMarkets.com

The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight repo
572

LLY Earnings

$1.13
$1.25
$1.38
$1.50
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Available Jan 30, Pre-Market

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.